RxDoctor Payments Data

Caroline Jackson, DO

Family Medicine · Valrico, FLNPI 1619311396

Payments from drug & device makers

$8,767in general payments, 2019–2025

Across 442 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Convatec Inc.$1K
  • Pfizer$757
  • AstraZeneca$691
  • GSK$604
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$5316%
  • Food & beverage$8,23694%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,767 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$106,325
Medicare patients
215
Services billed
2,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$48,028
EliquisApixaban54$41,365
OzempicSemaglutide25$32,966
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$23,391
LinzessLinaclotide14$21,058
MyrbetriqMirabegron14$18,318
Spiriva RespimatTiotropium Bromide34$17,498
XareltoRivaroxaban17$11,390
Breo ElliptaFluticasone/Vilanterol15$6,702
SymbicortBudesonide/Formoterol Fumarate15$4,421
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,092
Levothyroxine Sodium275$2,884
Lisdexamfetamine Dimesylate12$2,730
Ventolin HfaAlbuterol Sulfate25$2,643
SynthroidLevothyroxine Sodium28$2,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$343$48,02838 claims
PfizerEliquis$757$41,36554 claims
Novo NordiskOzempic$1,078$32,96625 claims
GSKTrelegy Ellipta, Breo Ellipta$604$30,09234 claims
AbbVieLinzess, Synthroid$1,053$23,52142 claims
Astellas Pharma US IncMyrbetriq$170$18,31814 claims
Boehringer IngelheimSpiriva Respimat$84$17,49834 claims
Johnson & JohnsonXarelto$98$11,39017 claims
AstraZenecaSymbicort$691$4,42115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Valrico

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →